Surgical endocrine ablation for advanced breast cancer.
نویسنده
چکیده
منابع مشابه
Breast cancer in limited-resource countries: treatment and allocation of resources.
Treating breast cancer under the constraints of significantly limited health care resources poses unique challenges that are not well addressed by existing guidelines. We present evidence-based guidelines for systematically prioritizing cancer therapies across the entire spectrum of resource levels. After consideration of factors affecting the value of a given breast cancer therapy (contributio...
متن کاملComparative trial of endocrine versus cytotoxic treatment in advanced breast cancer.
Ninety-two women with advanced breast cancer were allocated at random to receive either cytotoxic or endocrine treatment. Out of 45 women included in the cytotoxic treatment group, 22 (49%) achieved complete or partial remission of their disease, whereas of the 47 included in the endocrine treatment group, only 10 (21%) achieved such remission. Significantly longer survival times in the cytotox...
متن کاملGoserelin plus endocrine treatments maintained long-term clinical benefit in a male patient with advanced breast cancer
BACKGROUND Goserelin plus aromatase inhibitors (AI) have already been used in male advanced breast cancer, but the cases that fulvestrantin male breast cancer are rare. CASE PRESENTATION Here we report a case of long-term (3 years) response to Goserelin plus continuing endocrine treatments given for a male advanced breast cancer. The patient prolongs his life with high life quality, and has m...
متن کاملExpanding role of ovarian suppression/ablation in premenopausal ER-positive breast cancer: issues and opportunities.
Luteinizing hormone-releasing hormone analogs (LHRHa) are often used alone or in combination with tamoxifen to suppress ovarian function in premenopausal women with endocrine-responsive breast cancer. However, aromatase inhitiors (AIs) are now the preferred first-line endocrine treatment for postmenopausal women with breast cancer. Their benefits over tamoxifen in postmenopausal patients and th...
متن کاملCombined endocrine therapy for breast cancer--new life for an old idea?
Endocrine therapy has been a mainstay of breast cancer treatment for more than 100 years. The first interventions, oophorectomy for premenopausal women and pharmacologic doses of estrogen for postmenopausal women, have been supplanted by targeted therapy, including selective estrogen receptor modulators (SERMs) like tamoxifen, luteinizing hormone-releasing hormone (LHRH) agonists, and aromatase...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Postgraduate medical journal
دوره 33 382 شماره
صفحات -
تاریخ انتشار 1957